A phase 2 study of vatalanib in metastatic melanoma patients

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

J M Wood, Guido Bold, Elisabeth Buchdunger et al. · PubMed · 2000 · 847 citations

Medicine, Oncology, Pharmacology +16

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

Tim Eisen, T. Ahmad, Keith T. Flaherty et al. · British Journal of Cancer · 2006 · 636 citations · Full text

Medicine, Oncology, Pharmacology +15

A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma

Kimberly A. Varker, Jennifer E. Biber, Cheryl Kefauver et al. · Annals of Surgical Oncology · 2007 · 143 citations

Medicine, Oncology, Pharmacotherapy +16

LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)

Sanjiv S. Agarwala, Ulrich Keilholz, E Gilles et al. · European Journal of Cancer · 2009 · 137 citations

Medicine, Biomedical Sciences, Oncology +13

A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM)

C. Conrad, Henry S. Friedman, David A. Reardon et al. · Journal of Clinical Oncology · 2004 · 109 citations

Medicine, Oncology, Pharmacology +16